Lannett Company Inc (NYSE: LCI), a company that develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced yesterday that it has named John Kozlowski as its new chief financial officer effective 31 August 2019.
Kozlowski succeeds Martin Galvan, who will retire on 30 August 2019, following the planned submission of the company's Form 10-K for fiscal year 2019. He presently serves as the company's chief of staff and strategy officer.
Prior to joining Lannett, Kozlowski held senior finance positions with Finisar Australia (formerly Optium Australia) and Optium Corporation. He has a Master of Business Administration degree from Rider University and a Bachelor's degree in finance from James Madison University.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling